Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

IN10018 Kombinationsterapi ved avanceret EGFR-mutationspositiv NSCLC

9. november 2026 opdateret af: InxMed (Shanghai) Co., Ltd.

Et multicenter, åbent, fase Ib/II klinisk forsøg til evaluering af sikkerhed, tolerance, farmakokinetik og antitumoreffektivitet af IN10018 kombineret med tredjegenerations EGFR-TKI hos patienter med avanceret EGFR-mutationspositiv NSCLC

This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study includes 2 parts: Phase Ib-Dose Confirmation and Phase II-Dose Expansion. And 3 cohorts are set up in this study as cohort 1 to enroll subjects currently accepting third-generation EGFR-TKI (Furmonertinib is proposed) as first-line treatment, cohort 2 to enroll subjects who previously accepted third-generation EGFR-TKI treatment and 1-2 lines chemotherapy, and cohort 3 to enroll treatment-naive advanced EGFR mutation-positive NSCLC subjects.

The phase Ib-dose confirmation part will be conducted in cohort 2 and aim to determine the recommended phase II dose (RP2D) of IN10018 in combination with Furmonertinib. Phase II-Dose Expansion part will be conducted in cohort 1-3 and further explore the antitumor efficacy, safety and PK of IN10018 in combination with Furmonertinib in subjects with previously-treated or naïve advanced EGFR mutation-positive NSCLC.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

110

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Shanghai, Kina
        • Shanghai Pulmonary Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

  1. Be able to understand and be willing to sign informed consent.

  2. Male or female aged ≥ 18 years old at the time of signing informed consent.

  3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC, who is not suitable for radical surgery or radiotherapy.

  4. Documented EGFR mutations known to be associated with EGFR-TKI sensitivity, including Ex19del or L858R. Except for EGFR-TKI sensitive mutation, coexisting with other EGFR mutation types such as T790M can be allowed.

  5. Prior systemic antitumor therapy allowed are listed as follows:

    • Cohort 1: Subjects who are on the treatment of Furmonertinib as the first-line treatment setting.
    • Cohort 2: Subjects failed in third-generation EGFR-TKI treatment and also failed in or were intolerant to 1-2 lines of chemotherapy.
    • Cohort 3: subjects who haven't accepted any systemic therapy before. Prior adjuvant or neoadjuvant chemotherapy is permitted if an interval from the lost dose of adjuvant or neoadjuvant chemotherapy to the first documented PD is >6 months.
  6. Measurable lesions at baseline according to RECIST 1.1 criteria.

  7. Has an ECOG performance status of 0 or 1.

  8. Estimated life expectancy is more than 3 months.

  9. Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to the first dose of study treatment/randomization.

Exclusion Criteria

  1. Have experienced major surgical procedures or major trauma within 28 days prior to the first dose of study treatment/randomization.

  2. Have received the following prior systemic antitumor therapy:

    • Cohort 1: Have received chemotherapy, target therapy besides Furmonertinib, immunotherapy, biological therapy, and other antitumor drugs.
    • Cohort 2: Have received chemotherapy, targeted therapy, immunotherapy, biological therapy, and other antitumor drugs within 28 days prior to the first dose of study treatment.
    • Cohort 3: Have received systemic antitumor therapy for locally-advanced or metastatic NSCLC including chemotherapy, target therapy, immunotherapy, biotherapy, etc.
  3. Cohort 2 only: Presence of other gene mutations, including ALK mutation, MET amplification, HER2 amplification, RAS mutation, etc. after progression on prior third-generation EGFR-TKI treatment.

  4. Cohort 3 only:Has received the treatment of EGFR-TKI。

  5. Prior FAK inhibitors treatment.

  6. Have received systemic administration of potent inhibitors/inducers of CYP3A4, or P-gp inhibitors within 14 days prior to the first dose of treatment/randomization or are expected to receive systemic administration of these drugs during study treatment.

  7. Has received radiotherapy for study disease or radiotherapeutic area covered for more than 30% of the bone marrow within 28 days prior to the first dose of study treatment/randomization.

  8. Has had interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring steroid therapy; or diagnosis of clinically active ILD during the screening period.

  9. Has a prior history of other malignancy within 3 years prior to signing informed consent.

  10. Has known symptoms of spinal cord compression, active central nervous system (CNS) metastases, and/or carcinomatous meningitis.

  11. Has a history of severe cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment/randomization.

  12. Has known uncontrollable pleural effusion, pericardial effusion, and ascites.

  13. Has hemoptysis within 1 month prior to the first dose of study treatment/randomization with a blood volume of ≥2.5 mL every time or expected to require continuous hemostasis therapy during the study treatment.

  14. Has active infections that are poorly controlled by systemic treatment.

  15. Has active tuberculosis.

  16. Known allergy, hypersensitivity or intolerance to IN10018 and/or third-generation EGFR-TKI, or their ingredients.

  17. Pregnant or lactating women.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental Group in cohort 1, cohort 2, and cohort 3

IN10018+Furmonertinib

orally taken once daily

Andre navne:
  • BI 853520

orally taken once daily

Aktiv komparator: Control Group in cohort 3

Furmonertinib

orally taken once daily

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Recommended phase II dose (RP2D) of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced EGFR mutation-positive NSCLC.
Tidsramme: 3 years

Evaluate the number of patients with dose-limited toxicities (DLTs); Determine the RP2D of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced NSCLC.

3 years
ORR of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced EGFR mutation-positive NSCLC.
Tidsramme: 3 years

Defined as the proportion of subjects with complete response (CR) or partial response (PR)

3 years
Tumor Shrinkage Rate (TSR) of IN10018 in combination with third-generation EGFR-TKI in cohort 3 of advanced treatment-naive EGFR mutation-positive NSCLC.
Tidsramme: 3 years

Defined as the percentage of subjects with the best shrinkage rate of target lesions ≥ 70% and simultaneously with a best response of partial response (PR) or complete response (CR).

3 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PFS of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Tidsramme: 3 years

Defined as the time from the first dose of study treatment/randomization to first documentation of disease progression or to death due to any cause, whichever comes first.

3 years
DOR of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Tidsramme: 3 years

Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.

3 years
DCR of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Tidsramme: 3 years

Defined as the proportion of patients with CR, PR, or stable disease (SD).

3 years
OS of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Tidsramme: 3 years

Defined as the time from the first dose of study treatment/randomization to the date of death due to any cause.

3 years
Number of patients with adverse event
Tidsramme: 3 years

The number of participants who experienced AEs is presented.

3 years
PK: AUC of IN10018 following single dose administration and at steady state
Tidsramme: 3 years

Area under the concentration-time curve (AUC)

3 years
PK: Cmax of IN10018 following single dose administration and at steady state
Tidsramme: 3 years

Maximum concentration (Cmax)

3 years
PK:Ctrough of IN10018 following single dose administration and at steady state
Tidsramme: 3 years

Trough concentration (Ctrough)

3 years
PK:Tmax of IN10018 following single dose administration and at steady state
Tidsramme: 3 years

Time to Cmax (Tmax)

3 years
PK:t1/2 of IN10018 following single dose administration and at steady state
Tidsramme: 3 years

Elimination half-life (t1/2).

3 years
PK:CL/F of IN10018 following single dose administration and at steady state
Tidsramme: 3 years

apparent clearance (CL/F)

3 years
PK:Vd/F of IN10018 following single dose administration and at steady state
Tidsramme: 3 years

Apparent volume of distribution (Vd/F)

3 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Caicun Zhou, Shanghai Pulmonary Hospital, Shanghai, China

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. juli 2023

Primær færdiggørelse (Faktiske)

20. september 2025

Studieafslutning (Anslået)

31. december 2026

Datoer for studieregistrering

Først indsendt

8. august 2023

Først indsendt, der opfyldte QC-kriterier

8. august 2023

Først opslået (Faktiske)

16. august 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • IN10018-014

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .